Background. Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among organ transplant recipients. Multicenter prospective surveillance data to determine disease burden and secular trends are lacking. Methods. The Transplant-Associated Infection Surveillance Network (TRANSNET) is a consortium of 23 US transplant centers, including 15 that contributed to the organ transplant recipient dataset. We prospectively identified IFIs among organ transplant recipients from March, 2001 through March, 2006 at these sites. To explore trends, we calculated the 12-month cumulative incidence among 9 sequential cohorts. Results. During the surveillance period, 1208 IFIs were identified among 1063 organ transplant recipients. The most common IFIs were invasive candidiasis (53%), invasive aspergillosis (19%), cryptococcosis (8%), nonAspergillus molds (8%), endemic fungi (5%), and zygomycosis (2%). Median time to onset of candidiasis, aspergillosis, and cryptococcosis was 103, 184, and 575 days, respectively. Among a cohort of 16,808 patients who underwent transplantation between March 2001 and September 2005 and were followed through March 2006, a total of 729 IFIs were reported among 633 persons. One-year cumulative incidences of the first IFI were 11.6%, 8.6%, 4.7%, 4.0%, 3.4%, and 1.3% for small bowel, lung, liver, heart, pancreas, and kidney transplant recipients, respectively. One-year incidence was highest for invasive candidiasis (1.95%) and aspergillosis (0.65%). Trend analysis showed a slight increase in cumulative incidence from 2002 to 2005. Conclusions. We detected a slight increase in IFIs during the surveillance period. These data provide important insights into the timing and incidence of IFIs among organ transplant recipients, which can help to focus effective prevention and treatment strategies.
Bibliographical noteFunding Information:
Potential conflicts of interest. P.G.P. has received grant support from Merck, Pfizer, Schereing-Plough, and Astellas and served as an adhoc advisor for Novartis, Basilea, Merck, Pfizer, and Astellas. D.R.A. has received grant support and served as an ad hoc advisor for Merck, Pfizer, and Schering-Plough. T.F.P. has received research support and honoraria from Merck, Pfizer, Schering-Plough, and Nektar Therapeutics and has served as a consultant for Basilea, Merck, Nektar, and Pfizer. K.A.M. has received grant support from Merck and Enzon and served as an ad hoc advisor and/or consultant for Astellas, Basilea, Enzon, Merck, Pfizer, and Schering-Plough. J.I.I. has received honoraria from Astellas, Enzon, Pfizer, and Scher-ing-Plough. VAM is on the speakers’ bureau for Amgen, Merck, Pfizer, Schering-Plough, and Celgene. All other authors: no conflicts.